Engflag

Augmentin Nourrisson

Quick links to important sections

Augmentin Nourrisson

Augmentin Nourrisson_EN

Method of action: Antibacterial Broad Spectrum (Bactericidal), Bactericidal, Bactericidal Broad Spectrum

Treatment option: Abortion, Abscess, Lung Abscess, Bronchitis, Bronchopneumonia, Vaginitis, Community Acquired Pneumonia, Gonorrhea, Dysentery, Impetigo

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Augmentin Nourrisson

What is Augmentin Nourrisson?

Augmentin Nourrisson is a prescription antibiotic specifically formulated for use in infants. It belongs to a group of medicines known as penicillins and is characterized as a broad-spectrum antibacterial agent. This medication is designed to treat various bacterial infections by targeting and eliminating the bacteria responsible for the illness.

Composition and Mechanism

This medication is a combination product consisting of two primary active ingredients that work together to enhance its effectiveness:

  • Amoxicillin: A semi-synthetic antibiotic from the penicillin family. It works by interfering with the ability of bacteria to form stable cell walls, which is essential for their survival.
  • Clavulanic Acid: A beta-lactamase inhibitor. While it has little antibacterial activity on its own, its role is to protect amoxicillin from being destroyed by certain enzymes (beta-lactamases) produced by some resistant bacteria.

By combining these two components, the medication can remain effective against bacterial strains that would otherwise be resistant to amoxicillin alone.

Therapeutic Use

Augmentin Nourrisson is utilized to treat a variety of acute and chronic bacterial infections in infants. Its broad-spectrum nature allows it to be effective against a wide range of Gram-positive and Gram-negative pathogens. Common areas of application include:

  • Infections of the upper and lower respiratory tract.
  • Middle ear infections (otitis media).
  • Infections of the urinary tract.
  • Skin and soft tissue infections.

As an antibiotic, this medication is only effective against infections caused by bacteria; it does not treat viral infections such as the common cold or the flu.

What side effects are possible with Augmentin Nourrisson?

Possible Side Effects and Safety Information

The safety profile of Augmentin (amoxicillin/clavulanate) includes a range of adverse reactions primarily affecting the gastrointestinal tract and immune system, as documented in regulatory sources.

Adverse Reaction Classification

Classification Examples of Reactions
Very Common (≥ 1/10) Diarrhea (in adults)
Common (≥ 1/100 to < 1/10) Diarrhea (in children), Nausea, Vomiting, Mucocutaneous candidiasis
Uncommon (≥ 1/1,000 to < 1/100) Dizziness, Headache, Indigestion, Skin rash, Pruritus (itching), Urticaria, Moderate rise in liver enzymes (AST/ALT)
Rare (≥ 1/10,000 to < 1/1,000) Erythema multiforme, Reversible leucopenia/thrombocytopenia
Very Rare/Not Known Anaphylaxis, Stevens-Johnson syndrome, Toxic Epidermal Necrolysis, Hepatitis, Cholestatic jaundice, Convulsions, Drug-induced enterocolitis syndrome (DIES), Clostridioides difficile-associated diarrhea (CDAD), Kounis syndrome

Clinically Significant and Serious Reactions

Serious Hypersensitivity Reactions are a major concern and include anaphylaxis and severe cutaneous adverse reactions (SCAR), which require immediate cessation of the drug. Hepatotoxicity (hepatitis and cholestatic jaundice) is a documented risk, though rare, and may be delayed. Antibiotic-associated colitis (e.g., CDAD) is a reported serious gastrointestinal effect.

Safety Limitations and Specific Populations

Use is contraindicated in patients with a history of hypersensitivity to penicillins or previous Augmentin-associated jaundice/hepatic dysfunction. Caution is advised in patients with hepatic or renal impairment. Specific formulations may contain aspartame, requiring caution in patients with phenylketonuria (PKU). Drug-induced enterocolitis syndrome (DIES) has been reported, predominantly in children. Regulatory information notes that the risk of nausea may be reduced by administration at the start of a meal.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Augmentin Nourrisson

This section outlines the officially documented overdose profile for amoxicillin and clavulanate potassium, based strictly on government regulatory documents.

Overdose Scope

Documented overdose presentations: Gastrointestinal distress (diarrhea, vomiting, nausea, abdominal pain) and CNS effects (drowsiness, reversible hyperactivity), as well as urinary changes (cloudy urine, decreased output).

Physiological systems affected (as stated in label): Gastrointestinal, Central Nervous System, Renal, and Hepatic.

Dose-related or exposure-related factors (if applicable): Convulsions may occur in patients receiving high doses.

Population-specific overdose notes (if applicable): Convulsions are noted in patients with impaired renal function. Drug-Induced Enterocolitis Syndrome (DIES) is reported predominantly in children.

Emergency-response statements (as written in official documents): Seek emergency medical attention or contact the Poison Help line. Management is symptomatic and supportive.

When immediate medical help is required (label-derived phrasing only): Required when an overdose is suspected.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): The label notes the potential for serious outcomes including acute renal injury, severe hepatic dysfunction, and convulsions.

Regulatory basis (EMA / FDA / etc.): Information is consistent with FDA and EMA regulatory documentation.

Overdose-context constraints (as defined in official documents): Both amoxicillin and clavulanate potassium may be removed from circulation by hemodialysis. Maintaining adequate fluid intake is advised to manage crystalluria risk.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may present with gastrointestinal distress and CNS manifestations.
  • Severe outcomes include convulsions and rare cases of acute renal injury.
  • Seek emergency medical attention immediately if overdose is suspected.
  • Management is symptomatic and supportive, utilizing hemodialysis for drug removal.
  • Periodic assessment of renal, hepatic, and haematopoietic function is advised post-event.

Connection to the overall overdose profile (2–4 sentences): Regulatory documents define the overdose profile by listing symptoms ranging from common gastrointestinal distress to serious effects like acute renal injury and convulsions. This risk spectrum necessitates the explicit regulatory mandate to seek emergency medical attention immediately. Official management strategies documented in the label include supportive care, fluid management, and the use of hemodialysis.

Therapeutic Uses of Augmentin Nourrisson

Main Uses and Therapeutic Benefits

Augmentin Nourrisson is applied across domains where additional symptomatic support is needed for acute bacterial infections in situations involving certain distressing symptoms in infants and young children. This combination formula is commonly used for conditions presenting with acute episodes like Acute Otitis Media, Community-Acquired Pneumonia, sinusitis, cellulitis, and certain urinary tract infections.

“This formulation is often relevant in contexts marked by increased discomfort from infections applied in contexts involving heightened systemic burden.”

Quick Fact: Relief for Systemic Discomfort

This medication helps address symptoms related to systemic imbalance, such as fever and generalized malaise, and symptoms related to physical discomfort, like intense ear pain. Its use in these conditions contributes to easing the overall symptom load and supports the patient during difficult episodes by easing distress, which assists with maintaining functional stability and supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Augmentin Nourrisson?

Eligibility for Amoxicillin and Clavulanate Potassium (Augmentin Nourrisson) is strictly defined by regulatory documents, focusing on patient history and physiological status.

Contraindicated Populations

This medicine must not be used in patients with:

  • A history of serious hypersensitivity reactions (e.g., anaphylaxis) to amoxicillin, clavulanate, or any other beta-lactam antibacterial drugs (penicillins or cephalosporins).
  • A prior history of cholestatic jaundice or hepatic dysfunction specifically associated with amoxicillin/clavulanate therapy.

Eligibility and Restriction Rules

Population Group Eligibility Status (Regulatory Wording)
Infants/Children Use is established in neonates and infants (e.g., under 3 months), but specific oral suspension formulations are recommended.
Severe Renal Impairment Contraindicates the use of certain high-dose tablets; other formulations require mandatory dosage adjustment.
Hepatic Impairment Requires use with caution and regular monitoring of liver function.
Infectious Mononucleosis Not recommended due to an increased risk of skin rash.
Pregnancy/Lactation Use during pregnancy should be only if clearly needed. Caution is advised during lactation due to potential infant sensitization.

Eligibility also restricts patients with Phenylketonuria (PKU) from using formulations that contain aspartame.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interacting Medicinal Products and Substances

Co-administration of this product with several other categories of medicines requires caution or specific clinical monitoring as defined in regulatory labeling. The major documented interaction categories are:

  • Uricosurics/Renal Tubular Secretion Inhibitors: Probenecid specifically is not recommended for co-administration. It decreases the renal clearance of amoxicillin, resulting in increased and prolonged blood levels of amoxicillin only, without affecting clavulanic acid.
  • Oral Anticoagulants: Concomitant use with oral anticoagulants (e.g., coumarin derivatives like warfarin) is associated with reports of abnormal prolongation of prothrombin time (INR). Monitoring of this parameter is explicitly required during co-administration and after discontinuation.
  • Antigout Agents: Co-administration with allopurinol is linked to a substantially increased incidence of developing a skin rash, a risk stated in regulatory documents.
  • Oral Contraceptives: In common with other broad-spectrum antibiotics, this product may reduce the efficacy of combined oral contraceptives.
  • Methotrexate: Penicillins may reduce the renal excretion of methotrexate, potentially increasing its concentration and risk of toxicity.

Regulatory documentation mandates the monitoring of blood coagulation parameters when co-administered with oral anticoagulants and explicitly states that co-administration with probenecid is not recommended. This framework defines constraints for use, particularly concerning medicines that share or modify the body's drug elimination pathways.

Mechanism of Action

How Augmentin Nourrisson Works

Augmentin Nourrisson utilizes a synergistic dual mechanism to facilitate a bactericidal process against susceptible organisms. This action is accomplished by combining the two distinct mechanistic domains of its active components.

Mechanistic Domain 1: Inhibition of Cell Wall Synthesis

The Amoxicillin component acts as an inhibitor within structural integrity pathways. It covalently binds to Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for the final cross-linking steps of peptidoglycan synthesis in the bacterial cell wall. This binding inactivates the PBPs, blocking the molecular cascade necessary for maintaining structural rigidity. The subsequent failure of cell wall assembly leads to osmotic lysis and death of the susceptible organism.

Mechanistic Domain 2: Modulation of beta-Lactamase Enzymes

The Clavulanate component operates within the domain of enzyme system modulation. It functions as a suicide inhibitor by irreversibly binding to the active site of the bacterial beta-lactamase enzyme. This enzyme, if active, would hydrolyze and inactivate the Amoxicillin. By neutralizing the beta-lactamase, Clavulanate protects the Amoxicillin from degradation, thereby preserving the antibiotic's bactericidal activity across organisms exhibiting beta-lactamase activity.

Dosage and Administration Information

Administration Guidelines for Augmentin Nourrisson

Augmentin Nourrisson is a specific formulation of amoxicillin and clavulanate potassium intended for oral use as a powder for oral suspension. Its administration follows a specific protocol based on established clinical practice and pharmacological requirements.

Dosing and Frequency

The dosage is calculated based on the amoxicillin component and the patient’s body weight (mg/kg/day). For neonates and infants less than 12 weeks of age, the standard dose is 30 mg/kg/day of amoxicillin, typically divided and administered every 12 hours. Older children (12 weeks to < 40 kg) may receive higher mg/kg/day doses, up to 70 mg/kg/day of amoxicillin, depending on the severity of the infection and the formulation ratio (e.g., 7:1 or 4:1). The course of treatment typically does not exceed 14 days without clinical reassessment.

Administration Requirements

Requirement Instruction
Preparation The dry powder is reconstituted with a precise volume of water and shaken well prior to administration.
Timing Each dose is administered at the start of a meal to minimize potential gastrointestinal intolerance and optimize drug absorption.
Dosing Device A calibrated dosing device is used for accurate volumetric measurement of the suspension.
Renal Function Dose adjustments are applied for patients with severely impaired renal function (CrCl le 30 mL/min), and some oral suspension ratios may be restricted in this population.

Use Protocol

Usage involves reconstituting the powder, accurately measuring the specific mg/kg dose, and administering it at the start of a meal according to the prescribed 12-hour or 8-hour schedule. Different ratios of amoxicillin to clavulanate are not substitutable due to varying clavulanic acid content.

Recent Clinical Evidence

Augmentin Nourrisson: Recent Clinical Evidence

Augmentin Nourrisson, a pediatric formulation of amoxicillin and clavulanate potassium, is primarily studied for use in infants and young children to treat specific bacterial infections. The combination is designed to overcome bacterial resistance by protecting amoxicillin from inactivation by beta-lactamase enzymes. This mechanism is crucial for treating infections caused by resistant strains of common pediatric pathogens such as H. influenzae and M. catarrhalis.

Clinical research has historically concentrated on infections common in this age group. Evidence for use in infants younger than three months remains limited, with most studies focusing on children aged three months and older.

Efficacy Findings in Pediatric Trials

Studies, including randomized controlled trials, have investigated the use of amoxicillin/clavulanate in pediatric patients for common indications:

Indication Research Focus
Acute Otitis Media (AOM) Trials have explored the use of high-dose amoxicillin/clavulanate formulations to provide enhanced coverage against certain strains of S. pneumoniae that may be less susceptible to standard doses of amoxicillin alone.
Lower Respiratory Tract Infections Studies have examined its effectiveness in treating community-acquired pneumonia and other respiratory infections where beta-lactamase-producing bacteria are suspected.

Safety and Tolerability Profile

Research has explored the tolerability of various amoxicillin/clavulanate formulations, particularly in relation to the clavulanate component. Findings suggest that higher ratios of amoxicillin-to-clavulanate may be associated with reduced rates of gastrointestinal side effects, such as diarrhea, compared to older formulations. Potential for rare, but serious, adverse effects, including hypersensitivity reactions and hepatic dysfunction, have been documented across the pediatric population.

Frequently Asked Questions (FAQ)

Common questions about Augmentin Nourrisson (FAQ)

Q: Does taking this drug with food change how it works?

A: According to the official regulatory documents, this medication can be taken either with food or on an empty stomach. Taking it with food does not significantly impact how the drug is absorbed or how it works in the body. Official product information notes that taking the medication with a meal may help certain patients reduce the chance of mild stomach upset.

Q: Can I drink alcohol while taking this medication?

A: Official product information notes that alcohol may increase the risk of developing certain side effects, particularly central nervous system effects like dizziness or drowsiness. For this reason, regulatory information generally suggests limiting or avoiding alcohol consumption during treatment. The regulatory documents serve as a general reference for this concern.

Q: What should I do if I miss a dose?

A: Regulatory documents generally state that if a dose is missed, it should be taken as soon as it is remembered. However, if the next scheduled dose is approaching, the missed dose should be skipped, and the regular schedule resumed. Product information advises against taking two doses at once to make up for a missed dose.

Q: Will this drug make me feel sleepy or drowsy?

A: Studies and official product information indicate that somnolence, or sleepiness, is an undesirable effect that has been commonly observed. This potential side effect is noted in the product information. Because of this, regulatory information typically includes a warning about operating machinery or driving if affected by drowsiness.

Q: Can children under the age of 12 use this medication?

A: Official regulatory documentation specifies that the safety and effectiveness of this drug have not been definitively established in pediatric patients under 12 years of age. The lack of established data means the drug is generally not indicated for this group. A healthcare provider should always be consulted to determine suitability for any child.

Q: How should I store this medication?

A: To maintain the drug's effectiveness, official instructions advise storing the medication at controlled room temperature, typically ranging between 20^circC and 25^circC. The product label specifies storing in a dry environment and keeping it secured and out of reach of children.

How should Augmentin Nourrisson be stored and disposed of?

Storage and Disposal of Augmentin Nourrisson

The official storage conditions for Augmentin Nourrisson (amoxicillin/clavulanate potassium powder for oral suspension) depend on the product's state.

Storage Requirements

The unopened dry powder must be stored in its original container at a temperature not exceeding 25 C or 30 C and protected from moisture. Once the powder is mixed (reconstituted), the liquid suspension must be stored under refrigeration between mathbf2 C and mathbf8 C and must not be frozen.

Stability and Disposal

The refrigerated liquid suspension is stable for a maximum of 7 to 10 days. Any unused product remaining after this period must be discarded. The medicine must be kept out of the sight and reach of children. Disposal of unused or expired medicine must follow local pharmaceutical waste regulations; do not dispose of it via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagFrance

Equivalent of Augmentin Nourrisson found in:

A-Z Index: